Endothelial Cell Medium-rat

Name: Endothelial Cell Medium-rat
Brand: Sciencell Research Laboratories
SKU: 1021
Price: 158 USD
Availability: InStock

In Stock

Catalog No.

1021

Be the first to review this product

$158.00

Endothelial Cell Medium-rat (ECM-r) consists of 500 ml of basal medium, 25 ml of CS (Cat. #0025-cs), 5 ml of Endothelial Cell Growth Supplement-rat (ECGS-r, Cat. #1062) and 5 ml of penicillin/streptomycin solution (P/S, Cat. #0503).

Please select type of Medium below:

Complete kit (includes supplements) - 1021

Basal (no supplements) - 1021-b - $56.00

Phenol Red Free (includes supplements) - 1021-prf + $8.00

Basal Phenol Red Free (no supplements) - 1021-b-prf - $51.00

Glucose Free Complete Kit (includes supplements) - 1021-GF

No Glutamine Complete Kit (includes supplements) - 1021-NG

Qty

Product Description

Specifications

Technical Resources

Product Reviews

Publications

Endothelial Cell Medium-rat (ECM-r), when used with Endothelial Cell Growth Supplement-rat (ECGS-r, Cat #1062) and 25 ml of calf serum (CS, Cat #0025-cs) is a complete medium designed for optimal growth of normal rat endothelial cells in vitro. It is a sterile, liquid medium which contains essential and non-essential amino acids, vitamins, organic and inorganic compounds, hormones, growth factors, trace minerals and a low concentration of calf serum (5%). The medium is HEPES and bicarbonate buffered and has a pH of 7.4 when equilibrated in an incubator with an atmosphere of 5% CO2/95% air. The medium is formulated (quantitatively and qualitatively) to provide an optimally balanced nutritional environment that selectively supports the growth of normal rat endothelial cells in vitro.

More Information
Catalog No.	1021
Country of Manufacture	United States
Product Code	ECM-r
Size/Quantity	500 ml
Product use	This product is for research use only. It is not approved for use in humans, animals, or in vitro diagnostic procedures.
Storage	Store the basal medium at 4°C, the ECGS-r, the FBS and the P/S solution at -20°C. Protect from light.
Shipping	Basal medium: room temperature. Supplements: dry ice.

1. Perumal, V., Ravula, A. R., Agas, A., Kannan, M., Liu, X., I, S. S., Vijayaraghavalu, S., Haorah, J., Zhang, Y., & Chandra, N. (2023). Transferrin-Grafted Albumin Nanoparticles for the Targeted Delivery of Apocynin and Neuroprotection in an In Vitro Model of the BBB. Micro, 3(1), 84-106. https://doi.org/10.3390/micro3010008

Traumatic brain injury (TBI) is a major cause of morbidity and mortality worldwide, affecting over 10 million people annually, with an estimated cost of $76.5 billion. Al... More

Traumatic brain injury (TBI) is a major cause of morbidity and mortality worldwide, affecting over 10 million people annually, with an estimated cost of $76.5 billion. Although apocynin freely transverses the blood–brain barrier (BBB), its application is limited due to its rapid elimination, low terminal half-life (t1/2 = 6.7 min), narrow dose–response relationship, and cytotoxicity, thereby requiring repeated dosages. With this study, we aimed to develop transferrin-functionalized nanoparticles encapsulating apocynin to treat neuroinflammation for targeted drug delivery to sites of brain injury. As a preliminary approach, we endeavored to optimize the formulation parameters of apocynin-loaded albumin nanoparticles prepared through the desolvation method. The nanoparticles were characterized for their size, polydispersity, surface charge, drug loading and in vitro drug release. In this study, we also investigated the anti-inflammatory and neuroprotective effects of free apocynin and nanoparticle-loaded apocynin in neuronal cells. We show that the developed formulation displayed monodispersed, nanosized particles with higher entrapment efficiency, loading, stability, and sustained release profiles. The permeability of the nanoparticles across HBMECs reached the maximum at 67%. The in vivo evaluation revealed the enhanced uptake of transferrin-anchored nanoparticles in the brain tissues when compared with unmodified nanoparticles after I.V. administration. In vivo nanoparticle localization studies using a blast TBI (bTBI) model and confocal fluorescence microscopy have shown that tf-apoANPs are successful in delivering relatively high amounts of nanoparticles to the brain parenchyma and glial cells compared to non-targeted nanoparticles. We also establish that targeted nanoparticles accumulate in the brain. In conclusion, tf-apoANPs are efficacious carriers for targeted delivery across the blood–brain barrier to potentially treat neuroinflammation in brain injury and other diseases. Keywords: apocynin; nanoparticle; albumin; HPLC; desolvation method; targeted delivery; biodistribution; neuroprotection Less

ScienCell Research Laboratories (SRL) takes pride in being a resource for researchers all over the world. The publications listed here are not meant as an endorsement or confirmation of the reliability of the products.